Compound library / Bone Health

Teriparatide (Forteo)

Recombinant human PTH(1-34) fragment, FDA-approved for osteoporosis; the most-studied anabolic bone agent. Stimulates osteoblast activity to build new bone. Explored by some for faster fracture healing.

CategoryBone Health
Regulatory standingNo approved product cited
Typical routeSubcutaneous
Half-life~1 hour
Common dose range20 mcg once daily (approved dose)
Typical cycle lengthUp to 24 months per FDA label

BioHack Track models Teriparatide (Forteo) at a half-life of 1 hours, so every dose you log is decayed against that curve and the app shows estimated active levels — not just what you typed.

No approved product cited

No FDA-approved product for this compound is cited on this page, and no approved human dose is quoted. Treat the range below as research and community practice rather than a prescribed dose.

Reconstitution

Supplied as a pre-filled pen; no reconstitution needed.

Storage

Refrigerate; do not freeze. Pen stable in use for 28 days.

Cautions

Prescription medication with a boxed warning for osteosarcoma risk (based on rat data). Should not be used in patients with prior radiation to the skeleton or skeletal malignancy. Always follow with an antiresorptive agent.

Track Teriparatide (Forteo) in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.

Others in Bone Health

Look up the research

These open a search of each database for Teriparatide (Forteo) — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.

Work it out

Where these figures come from

The half-life, route and dose range on this page are compiled from published pharmacokinetic literature, manufacturer and product monographs where one exists, and the ranges commonly reported in clinical and research use. They are kept as a range rather than a single figure because that is what the sources actually support — a half-life varies with route, formulation and the person.

These are not citations, and this page is not a review of the evidence. Where a number matters to you, follow the database links above and read the source. We say so plainly rather than dressing a compiled reference up as one.

Nothing on this page has been reviewed by a named clinician. It is a reference for people already tracking a protocol, not a recommendation to start one.

Published by Creative Images LLC · Last updated · Corrections: support